Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

1. Cabrero, M.
2. Martin, A.
3. Briones, J.
4. Gayoso, J.
5. Jarque, I.
6. López, J.
7. Grande, C.
8. Heras, I.
9. Arranz, R.
10. Bernal, T.
11. Perez-Lopez, E.
12. López-Godino, O.
13. Conde, E.
14. Caballero, D.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.BBMT.2016.10.003 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

•